Phase II study of imatinib in patients with small cell lung cancer.
作者： Danny Rischin , Thierry Le Chevalier , Jason Hornick , Christopher Fletcher , Thomas Fischer
DOI:
关键词: CD117 、 Imatinib 、 Carcinoma 、 Clinical trial 、 Pathology 、 Chemotherapy 、 Medicine 、 Internal medicine 、 Oncology 、 Small-cell carcinoma 、 Phases of clinical research 、 Imatinib mesylate
摘要: Purpose: The purpose of our study was to assess the objective response imatinib administered patients with small cell lung cancer (SCLC). Experimental Design: Eligible were those SCLC who either had chemotherapy-naive extensive-stage or in a sensitive relapse. Patients enrolled on trial treated 600 mg daily. assessed using Southwest Oncology Group (SWOG) criteria after 3 and 6 weeks. Tumor specimens examined by immunohistochemistry for KIT receptor. Results: Nineteen entered study, including 16 men women. Nine previously untreated disease 10 A central pathology review confirmed only 14 19 patients. There no responses; however, one patient sensitive-relapse prolonged stabilization (>3 months) while therapy. median time progression 0.8 months (range, 0.6–1.3 1.2 0.2–4.1 groups, respectively. tissue samples from 4 (21%) receptor (CD117). Conclusions: observed antitumor activity this limited Phase II SCLC, which few tumors showed expression target. results are, thus, inconclusive about against targeted Further testing will focus demonstration setting histology.
aacrjournals.org参考文章(47)
T Hida, R Ueda, K Hibi, H Takagi, Y Ariyoshi, T Takahashi, Y Sekido, Coexpression of the stem cell factor and the c-kit genes in small-cell lung cancer. Oncogene. ,vol. 6, pp. 2291- 2296 ,(1991)
Geoffrey W. Krystal, Craig P. Organ, Susan J. Hines, Autocrine growth of small cell lung cancer mediated by coexpression of c-kit and stem cell factor. Cancer Research. ,vol. 56, pp. 370- 376 ,(1996)
Kaoru Shimokata, Yoshitaka Sekido, Toyoaki Hida, Motokazu Suyama, Ryuzo Ueda, Yuichi Obata, Toshitada Takahashi, Yutaka Ariyoshi, Preferential Expression of c-kit Protooncogene Transcripts in Small Cell Lung Cancer Cancer Research. ,vol. 51, pp. 2416- 2419 ,(1991)
LH Sobin, WD Travis, TV Colby, B Corrin, Y Shimosato, E Brambilla, Histological Typing of Lung and Pleural Tumours ,(1999)
E R Spindel, F Cuttitta, A F Gazdar, E A Sausville, J F Battey, A M Lebacq-Verheyden, Expression of the gastrin-releasing peptide gene in human small cell lung cancer. Evidence for alternative processing resulting in three distinct mRNAs. Journal of Biological Chemistry. ,vol. 261, pp. 2451- 2457 ,(1986) , 10.1016/S0021-9258(17)35956-2
Z. Fathi, M.H. Corjay, H. Shapira, E. Wada, R. Benya, R. Jensen, J. Viallet, E.A. Sausville, J.F. Battey, BRS-3: a novel bombesin receptor subtype selectively expressed in testis and lung carcinoma cells. Journal of Biological Chemistry. ,vol. 268, pp. 5979- 5984 ,(1993) , 10.1016/S0021-9258(18)53415-3
Stephen R. Bloom, Norman M. Bleehen, Mohammed A. Ghatei, Julie G. Reeve, Pamela H. Rabbitts, Eliott R. Spindel, Carles Cardona, Production of neuromedin B and neuromedin B gene expression in human lung tumor cell lines. Cancer Research. ,vol. 51, pp. 5205- 5211 ,(1991)
Edward L. Korn, Susan G. Arbuck, James M. Pluda, Richard Simon, Richard S. Kaplan, Michaele C. Christian, Clinical Trial Designs for Cytostatic Agents: Are New Approaches Needed? Journal of Clinical Oncology. ,vol. 19, pp. 265- 272 ,(2001) , 10.1200/JCO.2001.19.1.265
Adi F Gazdar, T. W. Moody, J. Battey, M. Draoui, H. Oie, G. Giaccone, Neuromedin B Is Present in Lung Cancer Cell Lines Cancer Research. ,vol. 52, ,(1992)
John P. Chute, Timothy Chen, Ellen Feigal, Richard Simon, Bruce E. Johnson, Twenty Years of Phase III Trials for Patients With Extensive-Stage Small-Cell Lung Cancer: Perceptible Progress Journal of Clinical Oncology. ,vol. 17, pp. 1794- 1794 ,(1999) , 10.1200/JCO.1999.17.6.1794